Γ
Content Highlights || Full Agenda
Breakout Session

3:30 PM

-

4:15 PM

Longevity

Engineering Longevity: Reprogramming the Foundations of Aging

Aging is increasingly understood as a gradual loss of biological stability. DNA accumulates damage, protein homeostasis collapses, and cells drift away from youthful identities as regulatory networks lose their balance over time. These changes ripple across tissues and organs, driving many of the diseases associated with aging. Today, new tools in synthetic biology, artificial intelligence, and gene editing are revealing how these systems might be stabilized, repaired, or even reset. Researchers are engineering enhanced DNA repair mechanisms inspired by long-lived species, using AI to map the trajectories of cellular aging and uncover rejuvenating interventions, and developing therapies that restore protein metabolism to protect vulnerable tissues such as the brain. This session explores how scientists are moving beyond simply slowing aging to engineering the biological systems that maintain cellular integrity. By targeting the underlying mechanisms that govern genome stability, proteostasis, and cellular identity, researchers are laying the groundwork for a new generation of longevity therapeutics designed to restore function and resilience across the lifespan.

Breakout Session

3:30 PM

-

4:15 PM

Longevity

Engineering Longevity: Reprogramming the Foundations of Aging

Aging is increasingly understood as a gradual loss of biological stability. DNA accumulates damage, protein homeostasis collapses, and cells drift away from youthful identities as regulatory networks lose their balance over time. These changes ripple across tissues and organs, driving many of the diseases associated with aging. Today, new tools in synthetic biology, artificial intelligence, and gene editing are revealing how these systems might be stabilized, repaired, or even reset. Researchers are engineering enhanced DNA repair mechanisms inspired by long-lived species, using AI to map the trajectories of cellular aging and uncover rejuvenating interventions, and developing therapies that restore protein metabolism to protect vulnerable tissues such as the brain. This session explores how scientists are moving beyond simply slowing aging to engineering the biological systems that maintain cellular integrity. By targeting the underlying mechanisms that govern genome stability, proteostasis, and cellular identity, researchers are laying the groundwork for a new generation of longevity therapeutics designed to restore function and resilience across the lifespan.

SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.

The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.

Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.

“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”

Eric Schmidt

Former CEO

"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."

Celestine Schnugg

Founder

"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."

Surge Biswas

Founder

"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."

Jacob Glanville

Founder & CEO

"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."

Bill Tai

Co-founder

"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira

Head of Digital Biology

"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."

Ola Wlodek

CEO

Who’s Coming to SynBioBeta?

And the BD and R&D Leads
That Will Be Your Customers and Partners: